Literature DB >> 11676841

Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis.

L S Chan1, N Robinson, L Xu.   

Abstract

Atopic dermatitis, a common, chronic, inflammatory skin disease that occurs with increasing prevalence, is characterized by hyperactivated cytokines of helper T cell subset 2 and is frequently associated with staphylococcal infection. An experimental animal model of atopic dermatitis induced by transgenically introduced cytokine is not available. We generated a transgenic mouse line expressing epidermal interleukin-4, a critical cytokine of helper T cell subset 2. Here we show that transgenic mice spontaneously developed a pruritic inflammatory skin disease reproducing all key features of human atopic dermatitis, including xerosis, conjunctivitis, inflammatory skin lesions, Staphylococcus aureus infection, histopathology of chronic dermatitis with T cell, mast cell, macrophage-like mononuclear cell, and eosinophil infiltration, and elevation of total serum IgE and IgG1. The onset and early progression of skin disease coincided with increased total serum IgE and IgG1. The mouse disease occurred at a 43% annual incidence rate and primarily affected the poorly haired skin: ear (100%), neck (65%), eye (53%), face (29%), tail (12%), leg (12%), and torso (6%). As a group the affected transgenic mice manifested with a skin disorder that fulfilled the clinical diagnostic criteria established for atopic dermatitis in human patients. Pending further characterization to authenticate it as a model of atopic dermatitis, this experimental animal model of pruritic inflammatory skin disease may facilitate investigations for the roles of interleukin-4 in cutaneous inflammation and skin infection in human patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676841     DOI: 10.1046/j.0022-202x.2001.01484.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  78 in total

1.  Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model.

Authors:  L Chen; O Martinez; L Overbergh; C Mathieu; B S Prabhakar; L S Chan
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice.

Authors:  Won Suck Yoon; Seung Seok Lee; Yang Seok Chae; Yong Keun Park
Journal:  Exp Mol Med       Date:  2011-02-28       Impact factor: 8.718

Review 3.  Pruritus in cutaneous T-cell lymphoma: a review.

Authors:  Kristen Ahern; Elaine S Gilmore; Brian Poligone
Journal:  J Am Acad Dermatol       Date:  2012-01-30       Impact factor: 11.527

4.  Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges.

Authors:  Mao-Qiang Man; Yutaka Hatano; Seung H Lee; Mona Man; Sandra Chang; Kenneth R Feingold; Donald Y M Leung; Walter Holleran; Yoshikazu Uchida; Peter M Elias
Journal:  J Invest Dermatol       Date:  2007-08-02       Impact factor: 8.551

Review 5.  Lessons from murine models of atopic dermatitis.

Authors:  Tao Zheng; Zhou Zhu
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.806

6.  Interleukin-4 Downregulation of Involucrin Expression in Human Epidermal Keratinocytes Involves Stat6 Sequestration of the Coactivator CREB-Binding Protein.

Authors:  Lei Bao; Jaime B Alexander; Huayi Zhang; Kui Shen; Lawrence S Chan
Journal:  J Interferon Cytokine Res       Date:  2016-02-26       Impact factor: 2.607

Review 7.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Authors:  Nicholas K Mollanazar; Peter K Smith; Gil Yosipovitch
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

8.  In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans.

Authors:  Miyuki Omori-Miyake; Masakatsu Yamashita; Yuichiro Tsunemi; Makoto Kawashima; Junji Yagi
Journal:  J Invest Dermatol       Date:  2013-11-26       Impact factor: 8.551

Review 9.  Animal models of atopic dermatitis.

Authors:  Haoli Jin; Rui He; Michiko Oyoshi; Raif S Geha
Journal:  J Invest Dermatol       Date:  2009-01       Impact factor: 8.551

10.  VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model.

Authors:  Lin Chen; Shao-xia Lin; Sanober Amin; Lut Overbergh; Giacomo Maggiolino; Lawrence S Chan
Journal:  Immunol Cell Biol       Date:  2010-01-12       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.